Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Comprehensive Genomic Data Deposition for Pancreatic Cancer Precision Medicine Studies: Clinical Trials NCT02451982 and NCT02648282

ABSTRACT: Comprehensive Genomic Data Deposition for Pancreatic Cancer Precision Medicine Studies: Clinical Trials NCT02451982 and NCT02648282

PROVIDER: PRJNA1095577 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Precision Medicine for Inherited Retinal Degenerations

Project description:Precision Medicine for Inherited Retinal Degenerations

| PRJNA736120 | ENA

Precision Medicine for Inherited Retinal Degenerations

Project description:Precision Medicine for Inherited Retinal Degenerations

| PRJNA736121 | ENA

The Brazilian Initiative on Precision Medicine (BIPMed)

Project description:The development of precision medicine strategies requires prior knowledge of the genetic background of the target population. However, despite the availability of data from admixed Americans within large reference population databases, we cannot use these data as a surrogate for that of the Brazilian population. This lack of transferability is mainly due to differences between ancestry proportions of Brazilian and other admixed American populations. To address the issue, a coalition of research centres created the Brazilian Initiative on Precision Medicine (BIPMed), an initiative of five Research Innovation and Dissemination Centers (RIDCs) supported by FAPESP.

2020-08-22 | GSE156652 | GEO

Genotyping of Metastatic Colorectal Cancer Patients for Precision Medicine Clinical Trials

Project description:The goal of delivering the right drug to the right cancer patient (precision medicine) requires a detailed understanding of how genomic alterations are linked to drug response. The purpose of this study is to intercept at point-of-care a large cohort of newly diagnosed mCRC patients to determine if it is possible to obtain personalized genetic information from each subject’s tumor (tissue and blood) to triage treatment choices. In case of target positivity, patients will be conveyed, whenever possible, to self-standing, independent, hypothesis-driven POC trials as soon as they exhibit resistance to standard of care treatment.

| 2259522 | ecrin-mdr-crc

The Brazilian Initiative on Precision Medicine (BIPMed)

Project description:The Brazilian Initiative on Precision Medicine (BIPMed)

| PRJNA658602 | ENA

Precision medicine for ABCA4 disease: modifier alleles

Project description:Precision medicine for ABCA4 disease: modifier alleles

| PRJNA717339 | ENA

Precision medicine for ABCA4 disease: modifier alleles

Project description:Precision medicine for ABCA4 disease: modifier alleles

| PRJNA717338 | ENA

Transcriptomic Analysis of Canine Osteosarcoma from a Precision Medicine Perspective Reveals Limitations of Differential Gene Expression Studies

Project description:Despite significant advances in cancer diagnosis and treatment, osteosarcoma (OSA), an aggressive primary bone tumor, has eluded attempts at improving patient survival for many decades. The difficulty in managing OSA lies in its extreme genetic complexity, drug-resistance, and heterogeneity, making it improbable that a single-target treatment would be beneficial for the majority of affected individuals. Precision medicine seeks to fill this gap by addressing the intra- and inter-tumoral heterogeneity to improve patient outcome and survival. Characterization of differentially expressed genes (DEGs) unique to the tumor provides insight into the phenotype and can be useful for informing appropriate therapies as well as development of novel treatments. Traditional DEG analysis combines patient data to derive statistically inferred genes that are dysregulated in the group; however, the results from this approach are not necessarily consistent across individual patients, thus contradicting the basis of precision medicine. Spontaneously occurring OSA in the dog shares remarkably similar clinical, histological, and molecular characteristics to the human disease and therefore serves as an excellent model. In this study, we use transcriptomic sequencing of RNA isolated from primary OSA tumor and patient-matched normal bone from seven dogs prior to chemotherapy to identify DEGs in the group. We then evaluate the universality of these changes in transcript levels across patients to identify DEGs at the individual level. These results can be useful for reframing our perspective of transcriptomic analysis from a precision medicine perspective by identifying variations in DEGs among individuals.

2022-04-10 | GSE199489 | GEO

Functional precision medicine identifies new therapeutic candidates for medulloblastoma

Project description:Functional precision medicine identifies new therapeutic candidates for medulloblastoma

| PRJNA635569 | ENA

PDX bank from urothelial cancer to guide precision medicine.

Project description:PDX bank from urothelial cancer to guide precision medicine.

| PRJNA754098 | ENA